Date Filed | Type | Description |
02/08/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/20/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
12/09/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
12/08/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/08/2021 |
8-K
| Quarterly results |
12/08/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
11/08/2021 |
SC 13D/A
| PPD, Inc. reports a 15.2% stake in SCIENCE 37 HOLDINGS, INC. |
10/28/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
10/27/2021 |
8-K
| Quarterly results |
10/18/2021 |
SC 13D
| PPD, Inc. reports a 15.1% stake in SCIENCE 37 HOLDINGS, INC. |
07/29/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
07/28/2021 |
8-K
| Quarterly results |
05/26/2021 |
DEFR14C
| Form DEFR14C - Revised information statement materials, definitive: |
05/25/2021 |
DEFM14C
| Form DEFM14C - Definitive information statement relating to merger or acquisition: |
05/19/2021 |
PRER14C
| Form PRER14C - Information statements: |
05/14/2021 |
PREM14C
| Form PREM14C - Preliminary information statements relating to merger or acquisition: |
04/29/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
04/28/2021 |
8-K
| Quarterly results |
04/27/2021 |
8-K
| Quarterly results |
04/21/2021 |
8-K
| Quarterly results |
04/16/2021 |
8-K
| Quarterly results |
04/15/2021 |
8-K
| Quarterly results |
03/08/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
03/08/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
02/26/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
02/23/2021 |
8-K
| Quarterly results |
02/12/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/12/2021 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
02/12/2021 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
02/12/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/11/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2021 |
GN
| AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections |
02/02/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|